ArticleOncology letters2026
Immunotherapy-based treatment patterns and clinical outcomes across lines of therapy in microsatellite stable metastatic colorectal cancer: A real-world study.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microsatellite stable (MSS) metastatic colorectal cancer (mCRC) hardly benefits from immune-monotherapy. Immune checkpoint inhibitor (ICI)-based combinations have been explored with mixed results. To evaluate the treatment patterns and outcomes across lines of immunotherapy in MSS mCRC, a retrospective real-world data analysis was performed in the present study. A total of 202 patients treated at Renmin Hospital of Wuhan University from June 2019 to December 2023 were included in the analysis, encompassing 38, 41 and 123 cases that received first-(1L), second-(2L) and third-line or above (3L+) ICI-based therapies, respectively. ICI combined with chemotherapy, ICI combined with chemotherapy and anti-VEGF(R)/EGFR/HER2 monoclonal antibody, and ICI combined with tyrosine kinase inhibitor (TKI) were the main options for the 1L, 2L and 3L+ cohorts, respectively. The objective response rates of the 1L, 2L and 3L+ treatment cohorts were 63.2, 22.0 and 11.4%, respectively, and the disease control rates of these three cohorts were 94.7, 75.6 and 70.7%, respectively. The median progression-free survival of the 1L, 2L and 3L+ cohorts was 11.1, 6.5 and 4.7 months, respectively, and overall survival (OS) was not reached, 16.0 and 11.9 months, respectively. After propensity score matching, patients who received ICI cross-line therapy at least once in the 3L+ cohort showed directional OS improvement (14.3 vs. 11.3 months; hazard ratio, 0.66; 95% confidence interval, 0.39-1.14; P=0.123) compared with those who did not receive ICI cross-line therapy. Grade ≥3 adverse events (AEs) occurred in 43.6% of patients, with thrombocytopenia, leukopenia and abnormal hepatic function being the most common. The incidence of immune-related AEs (irAEs) was 38.6% and that of grade ≥3 irAEs was 15.3%. These findings suggest that chemotherapy remains the cornerstone of 1L and 2L treatment for MSS mCRC, while the combination of ICI and TKI has developed into a major trend at the 3L+ setting with improved survival and controllable safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.